KOMZIFTI launch revenue of $5.8M in the first full quarter signals early commercial traction, but the stock will likely trade on upcoming clinical catalysts (EHA June 2026 data for ziftomenib/7+3, ASCO May 2026 darlifarnib data) rather than this quarter's financials. Monitor payer adoption trends and repeat prescription rates for signs of sustained uptake.
Price Chart
Executive Summary
Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial quarter), beating consensus revenue estimates. However, the net loss widened to $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025, driven by increased R&D and SG&A costs for the commercial launch and clinical trials. The company maintains a strong cash position of $580.8M plus $180M in anticipated collaboration payments, funding operations into 2028.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue of $5.8M from KOMZIFTI, first full commercial quarter
- 85 new patient starts and 157 total prescriptions in Q1 2026
- Net loss of $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025
- Cash and investments of $580.8M as of March 31, 2026, down from $667.2M at year-end 2025
- R&D expenses of $65.3M, up from $56.0M in Q1 2025, driven by KOMET-017 Phase 3 trials
- SG&A expenses of $31.6M, up from $22.8M in Q1 2025, reflecting commercialization costs
- Payer coverage >93% across plans covering >12 million lives
- Multiple clinical data readouts expected in 2026 across AML combination settings
Financial Impact
Q1 2026 total revenue of $18.3M ($5.8M product + $12.5M collaboration) vs consensus $25.9M; net loss of $73.3M vs consensus loss of $77.0M (EPS $-0.83 vs consensus $-0.88, a 5.7% beat)
Risk Factors
- Cash burn rate of ~$86M/quarter implies ~6-7 quarters of runway without additional collaboration milestones
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Differentiation syndrome boxed warning may constrain prescriber adoption
- Phase 3 KOMET-017 trial results not expected until 2028, creating binary event risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219422 |
| Document: kura-20260512.htm | 0001193125-26-219422 |
| Document: 0001193125-26-219422-index-headers.html | 0001193125-26-219422 |
| Document: 0001193125-26-219422-index.html | 0001193125-26-219422 |
| Document: 0001193125-26-219422.txt | 0001193125-26-219422 |
| 8-K Data (Synthetic) | 0001193125-26-219422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access